"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
-
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
-
Efficacy of tirzepatide 5, 10 and 15?mg versus semaglutide 2?mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 09; 24(9):1861-1868.
-
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
-
Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. JAMA. 2021 09 28; 326(12):1214-1215.
-
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
-
Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis. Int J Clin Pract. 2021 Sep; 75(9):e14060.
-
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 06; 28(6):1050-1061.
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 07 13; 394(10193):121-130.
-
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 07 13; 394(10193):131-138.